Akouos Inc - AKUS

Akouos Inc. (NASDAQ: AKUS) is a biotechnology company focused on developing gene therapies for individuals with disabling hearing loss. The company's lead product candidate, AK-OTOF, is designed to restore hearing function in individuals with sensorineural hearing loss caused by a mutation in the OTOF gene. Akouos is also developing gene therapies for other forms of hearing loss, including age-related and noise-induced hearing loss. The company was founded in 2016 and is headquartered in Boston, Massachusetts. Akouos went public in 2021 and is traded on the Nasdaq stock exchange.

NVST STRL JHMB CORN TTNP GDXU FENG RTK DBAW ICE DJIA TITN